Get started
Author

Steffi Lehmann

Observed name: Lehmann, Steffi
Observed institutions: Roche (Switzerland), Radboud University Nijmegen, University of Zurich, Radboud University Medical Center, ETH Zurich, Institute for Biomedical Engineering, ZHAW Zurich University of Applied Sciences
ORCID: 0000-0002-0411-027X
Observed ORCID: 0000-0002-0411-027X
OpenAlex ID: A5083722331
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2016 · Marina Bacac, Tanja Fauti, et al. · Clinical Cancer Research · 345
Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response
2013 · Anika Nagelkerke, Johan Bussink, et al. · Breast Cancer Research · 225
PDF
Hypoxia Induces a HIF-1-Dependent Transition from Collective-to-Amoeboid Dissemination in Epithelial Cancer Cells
2017 · Steffi Lehmann, Veronika te Boekhorst, et al. · Current Biology · 142
PDF
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents
2016 · Sylvia Herter, Laura Morra, et al. · Cancer Immunology Immunotherapy · 138
PDF
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
2016 · Steffi Lehmann, Ramanil Perera, et al. · Clinical Cancer Research · 71
Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events
2009 · Steffi Lehmann, Daniel P. Stiehl, et al. · Proceedings of the National Academy of Sciences · 63
111In-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages
2015 · Samantha Y. A. Terry, Otto C. Boerman, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 32
PDF
A novel surface functionalization platform to prime extracellular vesicles for targeted therapy and diagnostic imaging
2022 · Besmira Sabani, Michael Brand, et al. · Nanomedicine Nanotechnology Biology and Medicine · 21
MEndoB, a chimeric lysin featuring a novel domain architecture and superior activity for the treatment of staphylococcal infections
2024 · Christian Roehrig, Markus Huemer, et al. · mBio · 14
Pattern analysis accounts for heterogeneity observed in MRI studies of tumor angiogenesis
2012 · Marco Dominietto, Steffi Lehmann, et al. · Magnetic Resonance in Medicine · 12
Hypoxia Induces a HIF-1-Dependent Transition from Collective-to-Amoeboid Dissemination in Epithelial Cancer Cells
2017 · Lehmann, Steffi, Te Boekhorst, Veronika, et al. · Zurich Open Repository and Archive (University of Zurich) · 9
Recording Intracellular Molecular Events from the Outside: Glycosylphosphatidylinositol-Anchored Avidin as a Reporter Protein for In Vivo Imaging
2011 · Steffi Lehmann, Elisa Garcia Garayoa, et al. · Journal of Nuclear Medicine · 8
PDF
Multimodal optical system for quantitative discrimination of bilirubin species
2025 · Jan Zwicky, Daniel Fehr, et al. · Biomedical Optics Express · 1
Abstract 4141: Hypoxia-induced transition from collective to amoeboid single cell dissemination in epithelial cancer cells
2015 · Steffi Lehmann, Veronika A M te Boekhorst, et al. · Cancer Research · 1
Abstract LB-264: Development of 3D microtissue models to study the activity of novel tumor-targeted immunotherapeutics.
2013 · Inja Waldhauer, Laura Morra, et al. · Cancer Research · 1
Targeted delivery of peptidoglycan hydrolases (PGH) via engineered extracellular vesicles (EVs) to clear intracellular bacterial infections
2026 · Besmira Sabani, Martina Leone, et al. · Materials Today Bio
Multimodal optical system for quantitative discrimination of bilirubin species
2026 · Zwicky, Jan, Fehr, Daniel, et al. · ZHAW Digital Collection
Supplemental Figure 1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023 · Marina Bacac, Tanja Fauti, et al.
Supplementary Figures from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
2023 · Steffi Lehmann, Ramanil Perera, et al.
Supplementary Information from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
2023 · Steffi Lehmann, Ramanil Perera, et al.
Video 2 from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
2023 · Steffi Lehmann, Ramanil Perera, et al.
Video 3 from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
2023 · Steffi Lehmann, Ramanil Perera, et al.
Table S1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023 · Marina Bacac, Tanja Fauti, et al.
Video 1 from In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell–Mediated Tumor Killing
2023 · Steffi Lehmann, Ramanil Perera, et al.
Video 1 from A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
2023 · Marina Bacac, Tanja Fauti, et al.
Works count: 59
Citation count: 1,083
H-index: 10
I10-index: 10
Year
Topic
Type